Cargando…

Editorial: Progress of programmed cell death in antitumor immunity

Detalles Bibliográficos
Autores principales:	Yan, Fangfang, Mao, Chao, Leung, Elaine Lai-Han, Luo, Lianxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291824/ https://www.ncbi.nlm.nih.gov/pubmed/37377973 http://dx.doi.org/10.3389/fimmu.2023.1230490

Ejemplares similares

Editorial: Liver diseases and programmed cell death
por: Cao, Peng, et al.
Publicado: (2023)

Editorial: Cell network in antitumor immunity of pediatric and adult solid tumors
por: Pesce, Silvia, et al.
Publicado: (2023)

Editorial: The Impact of Angiogenic Growth Factors and Hypoxia on the Antitumor Immune Response
por: Albonici, Loredana, et al.
Publicado: (2022)

Programmed Cell Death Tunes Tumor Immunity
por: Liu, Jing, et al.
Publicado: (2022)

T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
por: Chi, Xiaoxia, et al.
Publicado: (2023)

Editorial: Nano- and Microparticle-Induced Cell Death, Inflammation and Immune Responses
por: Mulay, Shrikant R., et al.
Publicado: (2019)

Classification of tuberculosis-related programmed cell death-related patient subgroups and associated immune cell profiling
por: Shen, Jie, et al.
Publicado: (2023)

Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
por: Plackoska, Viktoria, et al.
Publicado: (2022)

Editorial: The role of immune cells in the progression of autoimmune diseases affecting the CNS
por: Kowal, Czeslawa, et al.
Publicado: (2022)

Editorial: Ionizing radiation reprograms tumor immune microenvironment by inducing immunogenic cell death
por: Yu, Fei, et al.
Publicado: (2023)

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
por: Zhang, Lei, et al.
Publicado: (2022)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
por: Zheng, Hao, et al.
Publicado: (2022)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity
por: Xia, Miaoran, et al.
Publicado: (2021)

Roles of CD4+ T cells as mediators of antitumor immunity
por: Kravtsov, Dmitriy S., et al.
Publicado: (2022)

Editorial: The Role of the EMT Program in Regulating the Immune Response in Carcinoma
por: Dongre, Anushka, et al.
Publicado: (2022)

Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity
por: Zheng, Hao, et al.
Publicado: (2022)

Antitumor Immunity Is Controlled by Tetraspanin Proteins
por: Schaper, Fleur, et al.
Publicado: (2018)

Epigenetics Regulates Antitumor Immunity in Melanoma
por: Chen, Yuhan, et al.
Publicado: (2022)

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study
por: Huang, Yu-Feng, et al.
Publicado: (2023)

Editorial: Innate Immunity Programming and Memory in Resolving and Non-Resolving Inflammation
por: Li, Liwu, et al.
Publicado: (2020)

Regulation of CD8(+) T Cells and Antitumor Immunity by Notch Signaling
por: Tsukumo, Shin-ichi, et al.
Publicado: (2018)

Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice
por: Zhang, Shi-Long, et al.
Publicado: (2022)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Editorial: Emerging strategies for cancer therapy targeting ferroptosis
por: Li, Manshan, et al.
Publicado: (2023)

Editorial: Iron Metabolism at the Crossroad of Innate Immune Response and Cancer Progression
por: Zacchi, Paola, et al.
Publicado: (2022)

Editorial: Immune Cells in the Mucosa
por: Pandiyan, Pushpa, et al.
Publicado: (2016)

Editorial: Regulation of Immunity by Non-Immune Cells
por: Dainichi, Teruki, et al.
Publicado: (2021)

Editorial: Immune Control of JC Virus Infection and Immune Failure during Progressive Multifocal Leukoencephalopathy
por: Taoufik, Yassine, et al.
Publicado: (2017)

Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response
por: Vienne, Margaux, et al.
Publicado: (2021)

Editorial: The Role of Biomembranes and Biophysics in Immune Cell Signaling
por: Shi, Yan, et al.
Publicado: (2021)

Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors
por: Xiao, Guixiu, et al.
Publicado: (2023)

Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
por: Sugii, Narushi, et al.
Publicado: (2020)

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
por: Gibbons Johnson, Rachel M., et al.
Publicado: (2017)

Editorial: Immunomodulation of Innate Immune Cells
por: Almeida, Catarina R., et al.
Publicado: (2020)

Editorial: Endothelial cells as innate immune cells
por: Lu, Yifan, et al.
Publicado: (2022)

Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
por: Héninger, Erika, et al.
Publicado: (2015)

Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
por: Ziani, Linda, et al.
Publicado: (2018)

Context-Specific and Immune Cell-Dependent Antitumor Activities of α1-Antitrypsin
por: Guttman, Ofer, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j4svrq1h94345d5agcp6c3bvov